What is Cepheid?
Founded in 1996 and based in Sunnyvale, California, Cepheid specializes in the development, manufacturing, and marketing of molecular systems and tests. The company's innovative solutions automate intricate manual procedures, enabling institutions of all sizes to conduct sophisticated genetic testing for organisms and genetic-based diseases. Cepheid's technology plays a crucial role in advancing diagnostic capabilities across various healthcare settings, positioning it as a key player in the molecular diagnostics market.
How much funding has Cepheid raised?
Cepheid has raised a total of $33M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$3.2M
Series B
$8.3M
Series C
$19.1M
Angel/Seed (1996): $2.5M with participation from Advanced Technology Ventures and Medtronic, Inc.
Series A (1997): $3.2M, investors not publicly disclosed
Series B (1998): $8.3M, investors not publicly disclosed
Series C (2000): $19.1M, investors not publicly disclosed
Key Investors in Cepheid
Advanced Technology Ventures
Advanced Technology Ventures (ATV) is a venture capital firm with a history of investing in technology markets, including healthcare. Their involvement suggests a focus on supporting early-stage growth and market leadership for innovative companies.
Medtronic, Inc.
Medtronic is a global leader in medical technology, offering a wide range of device-based medical therapies. Their investment in Cepheid indicates a strategic interest in molecular diagnostics and its integration with broader healthcare solutions.
What's next for Cepheid?
With a history of substantial capital injections, including its most recent major strategic investment, Cepheid is well-positioned for continued growth and innovation in the molecular diagnostics sector. The company's focus on automating complex genetic testing suggests a strategic emphasis on expanding its market reach and enhancing its product offerings. Future developments are likely to center on further refining its diagnostic platforms and potentially exploring new applications for its technology, leveraging its established enterprise-level funding to drive research and development and scale operations.
See full Cepheid company page
